Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2013; 59(3): 102-110

The anti-inflammatory effect of fullerene C60 on adjuvant arthritis in rats

Mamontova TV, Mykytiuk MV, Bobrova NO, Kutsenko LO, Vesnina LE, Kaĭdashev IP

    Research Institute for Genetic and Immunological Grounds of Pathology and Pharmacogenetics Ukrainian Medical Stomatological Academy, Poltava, Ukraine
DOI: https://doi.org/10.15407/fz59.03.102


Abstract

The anti-inflammatory properties of non-modified fullerene C60 (FC60) by adjuvant arthritis in Wistar rats have been studied. It was shown that the intraperitoneal introduction of FC60 (50 ng) reveals an anti-inflammatory and chondroprotective actions in the phase of systemic manifestation of adjuvant arthritis. The effect was carried out by limitation of inflammation of damaged limb, normalization of body weight, the decrease in body temperature. Introduction of FC60 promote the reduction of leukocyte level, the erythrocyte sedimentation rate, concentrations of sialic acids and the ceruloplasmin levels, processes degeneration of cartilaginous tissues of the joint of rats. It has been concluded that the therapeutic effectiveness of non-modified FC60 in experimental adjuvant arthritis is comparable with the action of water-soluble forms of fullerenes. The results substantiate the future investigations of non-modified FC60 for design of therapeutic agents for treatment of rheumatoid arthritis in clinics.

Keywords: nanoparticles, fullerene C60, adjuvant arthritis

Full text: (PDF, in Ukrainian)

References

  1. Berkalo L.V., Bobovich O.V., Bobrova N.O., Geiko O.A., Kaidashev I.P., Kutsenko L.O., Nozhinova O.A., Ryabenko V.V., Sokolenko V.M., Shinkevich V.I. Metodi klinichnih ta eksperimental'nih doslidzhen' v meditsini. Pid red. I.P. Kaidasheva. Poltava: Polimet, 2003. 320 p. Ya.V. Hmelevskogo. K.: Vishcha shk., 1985. 207 p.
    2.  
  2. Biologicheskaya himiya. Praktikum. Pod obshch. red. prof Ya.V. Hmelevskogo. K.: Vishcha shk., 1985. 207 p.
    3.  
  3. Bobrova N.A., Mikityuk M.V., Kutsenko L.A., Kaidashev I.P. Vliyanie fullerena S60 na protsessi svobodnoradikal'nogo okisleniya lipidov pri eksperimental'noi bronhial'noi astme. Patol. fiziologiya i eksperim. terapiya. 2012. N 3. P. 109-114.
    4.  
  4. Vesnina L.E., Mamontova T.V., Mikityuk M.V., Kutsenko N.L., Kutsenko L.A., Bobrova N.A., Berkalo L.V., Kaidashev I.P. Vliyanie fullerena S60 na funktsional'nuyu aktivnost' fagotsitarnih kletok. Eksperim. i klin. farmakologiya. 2011. 74, N 6. P. 26-29.
    5.  
  5. Vesnina L.E., Mamontova T.V., Mikityuk M.V., Bobrova N.A., Kutsenko L.A., Yaroshenko G.A., Kaidashev I.P. Fulleren S60 obladaet immunomoduliruyushchei aktivnost'yu pri ad'yuvantnom artrite u kris. Tam zhe. 2012. 75, N 8. P. 15-20.
    6.  
  6. Vesnina L.E., Mamontova T.V., Mikityuk M.V., Kutsenko L.O., Bobrova N.O., Kutsenko N.L., Kaidashev I.P. Stan perekisnogo okislennya lipidiv u mishei linii Balb/c ta vpliv fulerenu S60 pid chas imunnoi vidpovidi.Fiziol. zhurn. 2012. 58, N 3. P. 19-26.
    7.  
  7. Kovalenko V.M. Himion L.V., Lisenko G.I., Garmish O.O. Vpliv imunnogo statusu i lipidnih faktoriv na progresuvannya subklinichnogo aterosklerozu i rozvitok sertsevo-sudinnih zahvoryuvan' u patsiientiv iz revmatoidnim artritom.Ukr. revmatol. zhurn. 2011. 43, N 1. P. 52-59.
    8.  
  8. Kolb V.G., Kamishnikov V.S. Klinicheskaya biohimiya. Minsk: Belarus', 1976. 311 p.
    9.  
  9. Kutsenko N.L., Mikityuk M.V., Bobrova N.O., Kaidashev I.P. Vpliv fulereniv na rozvitok alergichnogo zapalennya v eksperimenti.Problemi ekologii ta meditsini. 2009. 13, N 5-6. P. 7-12.
    10.  
  10. Kutsenko L.A., Kaidashev I.P. Mesto tseruloplazmina sredi belkov ostroi fazi kak markera sistemnogo vospaleniya.Lab. diagnostika. 2011. N 3. P. 59-68.
    11.  
  11. Matishevs'ka O.P., Priluts'ka S.V., Grinyuk I.I. Fulereni S60 biologichno aktivni molekuli. I. Fiziko-himichni vlastivosti ta biodostupnist'.Biotehnologiya. 2010. 3, N 3. P. 18-26.
    12.  
  12. P riluts'ka S.V., Kichmarenko Yu.M., Boguts'ka K.I., Priluts'kii Yu.I. Fulereni S60 ta iogo pohidni yak protipuhlinni agenti: problemi ta perspektivi. Tam samo. 2012. 5, N 3. P. 9-17.
    13.  
  13. Biologicheskaya himiya. Praktikum. Pod obshch. red. prof. Bendele A.M. Animal models of rheumatoid arthritis.J. Musculoskel. Neuron Interact. 2001. 1, , 4. P. 377-385.
    14.  
  14. Bevaart L., Vervoordeldonk M.J., Tak P.P. Evaluation of therapeutic targets in animal models of arthritis. How does it relate to rheumatoid arthritis.Arthritis Rheumatism. 2010. 62, , 80. P. 2192-2205.
    15.   Card J.W., Zeldin D.C., Bonner J.C., Nestmann E.R. Pulmonary applications and toxicity of engineered nanoparticles.Amer. J. Physiol. Lung Cell Mol. Physiol. 2008. 295. P. L400-L411 CrossRef PubMed PubMedCentral  
  15. Chen H.H.C., Yu C., Ueng T.H., Chen S., Chen B.J., Huang K.J., Chiang L.Y. Acute and sub-acute toxicity study of water-soluble polyalkylsulfonated C60 in rats. Toxicol. Pathol. 1998. 26. P. 143–148. CrossRef PubMed
    16.  
  16. Cutolo M., Sulli A., Pizzorni C., Seriolo B., Straub R. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis.Ann. Rheum. Dis. 2001. 60. P. 729-735. CrossRef PubMed PubMedCentral
    17.  
  17. Dhavan A., Taurozzi J.S., Pandey A.K., Shan W., Miller S.M., Hashsham S.A., Tarabara V.V. Stable colloidal dispersion of C60 fullerenes in water: evidence for genotoxicity.Environ. Sci. Technol. 2006. 40. p. 7394-7401. CrossRef  
  18. Feketeova L., Jan.ova P., Moravcova P., Janegova A., Bauerova K., Poni.t S., Mihalova D., Janega P., Babal P. Effect of methotrexate on inflammatory cells redistribution in experimental adjuvant arthritis.Rheumatol. Int. 2011. 15. P. 220-228.
    19.  
  19. Gao J., Wang H-L., Iyer R. Suppression of proinflammatory cytokines in functionalized fullerene-exposed dermal keratinocytes.J. Nanomaterials. 2010. 2010. P. 9.15.
    20.  
  20. Johnston H.J, Hutchison G.R, Christensen F.M et al. Helinor J., Aschberger K., Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity.Toxicol. Sci. 2010. 114, ‡,2. P. 162-182.
    21.  
  21. Markovich Z., Traikovich V. Biomedical potential of reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials. 2008., 28. p. 3561-3573. CrossRef PubMed
    22.  
  22. Montanez M.I., Ruiz-Sanchez A.J., Perez-Inestrosa E. A perspective of nanotechnology in hypersensitivity reactions including drug allergy.Curr. Opin. Allergy Clin. Immunol. 2010. 10, 4. P. 297-302.
    23.  
  23. Naota M., Shimada A., Morita T., Inoue K., Takano H. Translocation pathway of the intratracheally instilled C60 fullerene from the lung into the blood circulation in the mouse: possible association of diffusion and caveolaemediated pinocytosis.Toxicol. Pathol. 2009. 37. P. 456-462. CrossRef PubMed
    24.  
  24. Phillipe L., Gegout-Pottie P., Guingamp C. Bordji K., Terlain B., Netter P., Gillet P. Relations between functional, inflammatory, and degenerative parameters during adjuvant arthritis in rats.Amer. J. Phisiol. 1997. 273. P. R1550-R1556.
    25.  
  25. Prylutska S.V., Grynyuk I.I., Matyshevska O.P., Prylutskyy Yu.I., Ritter U., Scharff P. Anti-oxidant properties of C60 fullerenes in vitro. Fullerenes, Nanotubes, and Carbon Nanostruct. 2008. 16, 5. 6. P. 698-705.
    26.  
  26. Rayan J.J., Bateman H.R., Stover A. Gomez G., Norton S.K., Zhao W., Schwartz L.B., Lenk R., Kepley C.L. Fulleren"u nanomaterials inhibit the allergic response.J. Immunol. 2007. 179. P. 665-672. CrossRef  
  27. Reddy G.K., Dhar S.C. Studies on carbohydrate moieties of glycoproteins in established adjuvant induced arthritis.Agents Actions. 1988. 25, 1.2. P. 63-70.
    28.  
  28. Rovensky J., Stancikova M., Rovenska E., Stvrtina S., Stvrtinova V., Svik K. Treatment of rat adjuvant arthritis with Flavonoid (DetralexR), Methotrexate, and their combination.Ann. NY Acad. Sciences. 2009. 1173. P. 798-804. CrossRef PubMed
    29.  
  29. Tak P.P., Klapwijk M.S. Broersen S.F.M., van de Geest Overbeek M., Firestein G.S. Apoptosis and p53 expression in rat adjuvant arthritis.Arthritis Res. 2000. 2. P. 229.235.
    30.  
  30. van Eden W., Waksman "B."N. Immune regulation inadjuvant-induced arthritis possible implications for innovative therapeutic strategies in arthritis.Arthritis Rheumatism. 2003. 48, , 7. P. 1788-1796.
    31.  
  31. Yudoh K., Karasawa R., Masuko K., Kato T. Water-soluble fullerene (C60) inhibits the osteoclast differentiation and bone destruction in arthritis.Int. J. Nanomedicine. 2009. 4. P. 233-239. CrossRef PubMed PubMedCentral
    32.  
  32. Yudoh K., Karasawa R., Masuko K., Kato T. Water-soluble fullerene ("R60) inhibits the development of arthritis in the rat model of arthritis.Ibid. P. 217-225.
    33.  
  33. Yudoh K., Shishido K., Murayama H., Yano M., Matsubayashi K., Takada H., Nakamura H., Masuko K., Kato T., Nishioka K. Water-soluble C60 fullerene degeneration of articular cartilage in osteoarthritis via down-regulation of chondrocyte catabolic activity and inhibition of cartilage degeneration during disease development.Arthritis Rheum. 2007. 56. P. 3307-3318. CrossRef PubMed
    34.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.